Beatriz M Zazueta

Suggest Changes
Learn More
OBJECTIVE To evaluate the longterm efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to(More)
  • 1